Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Sprinklr in a note issued ...

Investment analysts at William Blair dropped their Q1 2025 EPS estimates for shares of CARGO Therapeutics in a research note issued to investors on Thursday, March 13th. William Blair analyst S.

William Blair downgraded Udemy (UDMY) to Market Perform from Outperform after the company announced the appointment of Hugo Sarrazin as ...

We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...

The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.

Palantir (NASDAQ:PLTR) was upgraded to Market Perform from Underperform by William Blair, following the recent share price ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

The embedded finance company, which posted a loss last year, hired Citi to explore its strategic options and named an interim ...

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...